ESMO 2020 | 4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma

Jeffrey Weber, MD, PhD, of Perlmutter Cancer Center, New York, NY, updates us on the 4-year follow-up results of the randomized, Phase III CheckMate 238 study (NCT02388906), comparing adjuvant nivolumab versus ipilumumab in preventing recurrence of disease after complete resection in patients with stage III/IV melanoma. This study showed that nivolumab continued to demonstrate improved recurrence-free survival (RFS) and distant metastases-free survival (DMFS) vs ipilumumab at 4-years in patients with stage III/IV melanoma at high risk of reccurence. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).